Moleculin has closed enrolment of 89 subjects in Part A of its pivotal MIRACLE trial, targeting a comprehensive data readout in Q1 2027.

Unilabs joins Hub71+ Life Sciences as an anchor partner, with live collaborations already under way with mental health and biological-age testing startups.

Dubai-based DarDoc has launched a machine learning intelligence layer that proactively surfaces patient context between appointments, available to Lifestyle Rx members.

Knight Therapeutics will seek regulatory approval and commercialise mogamulizumab across Brazil, Mexico, Colombia and Argentina under an exclusive distribution pact.

Novo Nordisk will pay $300m upfront for global rights to HRS-1596, a once-weekly oral dual GLP-1/GIP agonist nearing Phase 1 trials.

PolarityBio's pivotal COVER DFUS II trial results will be presented on 16 October, ahead of the FDA's March 2027 PDUFA date for SkinTE.

Roche's oral BTK inhibitor fenebrutinib has received priority review acceptance for both relapsing and primary progressive MS, a first for the class.

Iopofosine I 131 showed an 87.5% overall response rate in BTK inhibitor-refractory Waldenström Macroglobulinemia, with a duration of response exceeding 16 months.

An interim read of 45 NEXICART-2 patients shows NXC-201 achieving an 89% complete response rate, with MRD-negativity pointing to a potential 98

Invivyd said VYD2311 met all primary and secondary endpoints in LIBERTY, with superior tolerability to Pfizer's COMIRNATY and a BLA filing now planned.

ZUPREME-1 Phase 2 results, published in The Lancet, show petrelintide cut body weight by up to 10.7% with placebo-comparable GI tolerability.

Updated Phase I/II data on ifezuntirgene inilparvovec show an 80% slowing of Huntington's disease progression at 36 months across 15 high-dose patients.